1. Home
  2. AADI vs LGCY Comparison

AADI vs LGCY Comparison

Compare AADI & LGCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AADI
  • LGCY
  • Stock Information
  • Founded
  • AADI 2011
  • LGCY 2009
  • Country
  • AADI United States
  • LGCY United States
  • Employees
  • AADI N/A
  • LGCY N/A
  • Industry
  • AADI Biotechnology: Pharmaceutical Preparations
  • LGCY
  • Sector
  • AADI Health Care
  • LGCY
  • Exchange
  • AADI Nasdaq
  • LGCY NYSE
  • Market Cap
  • AADI 59.4M
  • LGCY 67.3M
  • IPO Year
  • AADI N/A
  • LGCY 2024
  • Fundamental
  • Price
  • AADI $2.34
  • LGCY $8.58
  • Analyst Decision
  • AADI Hold
  • LGCY Strong Buy
  • Analyst Count
  • AADI 3
  • LGCY 2
  • Target Price
  • AADI $1.75
  • LGCY $9.10
  • AVG Volume (30 Days)
  • AADI 109.6K
  • LGCY 101.5K
  • Earning Date
  • AADI 11-06-2024
  • LGCY 11-14-2024
  • Dividend Yield
  • AADI N/A
  • LGCY N/A
  • EPS Growth
  • AADI N/A
  • LGCY 90.87
  • EPS
  • AADI N/A
  • LGCY 0.63
  • Revenue
  • AADI $25,070,000.00
  • LGCY $49,638,473.00
  • Revenue This Year
  • AADI $9.39
  • LGCY N/A
  • Revenue Next Year
  • AADI $6.15
  • LGCY N/A
  • P/E Ratio
  • AADI N/A
  • LGCY $13.61
  • Revenue Growth
  • AADI 7.80
  • LGCY 32.36
  • 52 Week Low
  • AADI $1.21
  • LGCY $3.60
  • 52 Week High
  • AADI $2.63
  • LGCY $10.37
  • Technical
  • Relative Strength Index (RSI)
  • AADI 58.75
  • LGCY N/A
  • Support Level
  • AADI $2.25
  • LGCY N/A
  • Resistance Level
  • AADI $2.45
  • LGCY N/A
  • Average True Range (ATR)
  • AADI 0.11
  • LGCY 0.00
  • MACD
  • AADI -0.01
  • LGCY 0.00
  • Stochastic Oscillator
  • AADI 39.89
  • LGCY 0.00

About AADI Aadi Bioscience Inc.

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

About LGCY LEGACY EDUCATION INC

Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.

Share on Social Networks: